Abstract
We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting.
Keywords: Activator, Imidazothiazole, SIRT1, Sirtuin, SRT1720, SRT2104.
Letters in Drug Design & Discovery
Title:The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate
Volume: 10 Issue: 9
Author(s): Meghan Duncan, Robert B. Perni, James L. Ellis, George P. Vlasuk, Michael R. Jirousek, Joseph J. Nunes, Jill C. Milne, Peter J. Elliot, Vipin Suri, Akanksha Gupta, Kristina Kriksciukaite, Marie Yeager, Pui Yee Ng, Angela Tornblom, Siva Lavu, Jesse J. Smith, Jeffrey Song, Thomas V. Riera, David P. Carney, Amy V. Lynch, Christopher J. Oalmann, Chi B. Vu, Jeremy S. Disch and Jean E. Bemis
Affiliation:
Keywords: Activator, Imidazothiazole, SIRT1, Sirtuin, SRT1720, SRT2104.
Abstract: We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting.
Export Options
About this article
Cite this article as:
Duncan Meghan, Perni B. Robert, Ellis L. James, Vlasuk P. George, Jirousek R. Michael, Nunes J. Joseph, Milne C. Jill, Elliot J. Peter, Suri Vipin, Gupta Akanksha, Kriksciukaite Kristina, Yeager Marie, Ng Yee Pui, Tornblom Angela, Lavu Siva, Smith J. Jesse, Song Jeffrey, Riera V. Thomas, Carney P. David, Lynch V. Amy, Oalmann J. Christopher, Vu B. Chi, Disch S. Jeremy and Bemis E. Jean, The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113100990021
DOI https://dx.doi.org/10.2174/15701808113100990021 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Dibenzothiepins with Antibiofilm Activity Demonstrated by Microbiological Assays and Molecular Modeling
Current Organic Chemistry Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Stem Cell Therapies
Recent Patents on Regenerative Medicine Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Decoding Psoriasis: Integrated Bioinformatics Approach to Understand Hub Genes and Involved Pathways
Current Pharmaceutical Design Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) The Functions of Bursal Hexapeptide (BHP) on Immune Response and the Molecular Mechanism on Immature B Cell
Protein & Peptide Letters The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives
Current Drug Metabolism The Nuclear Orphan Receptor NR4A1 and NR4A3 as Tumor Suppressors in Hematologic Neoplasms
Current Drug Targets Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Cellular Immunity and DNA Vaccines for the Treatment of HIV / AIDS
Current Medicinal Chemistry - Anti-Infective Agents Hydrogen Commonly Applicable from Medicine to Agriculture: From Molecular Mechanisms to the Field
Current Pharmaceutical Design Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Mast Cell's Role in Cytokine Release Syndrome and Related Manifestations of COVID-19 Disease
Current Pharmaceutical Design Genetic and Environmental Modifiers of Alzheimers Disease Phenotypes in the Mouse
Current Alzheimer Research Cancer Gene Therapy through Autonomous Parvovirus - Mediated Gene Transfer
Current Gene Therapy Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets Emerging Trends and Future Challenges of Nanovaccine Delivery <i>via</i> Nasal Route
Current Drug Targets